P2X purinergic receptor ligands: recently patented compounds

Bibliography

• Di Virgilio F, Chiozzi P, Ferrari D, Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001;97:587-600
   PubMed Web of Science ®Google Scholar
• Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007;87:659-797
   PubMed Web of Science ®Google Scholar
• Roux SJ, Steinebrunner I. Extracellular ATP: an unexpected role as a signaler in plants. Trends Plant Sci 2007;12(11):522-7
   PubMedGoogle Scholar
• Zimmermann H. Extracellular purine metabolism. Drug Dev Res 1996;39:337-52
   Web of Science ®Google Scholar
• Braun N, Zimmermann H. Microglial ectonucleotidases: identification and functional roles. Drug Dev Res 2001;53:208-17
   Google Scholar
• Abbracchio MP, Burnstock G, Verkhratsky A, Purinergic signalling in the nervous system: an overview. Trends Neurosci 2009;32(1):19-29
   PubMedGoogle Scholar
• Burnstock G. Purinergic nerves. Pharmacol Rev 1972;24(3):509-81
   PubMed Web of Science ®Google Scholar
• Holton P. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J Physiol 1959;145:494-504
   PubMed Web of Science ®Google Scholar
• Burnstock G. Physiological and pathological roles of purines: an update. Drug Dev Res 1993;28:195-206
   Web of Science ®Google Scholar
• Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998;50(3):413-92
   PubMed Web of Science ®Google Scholar
• Abbracchio MP. P1 and P2 receptors in cell growth and differentiation. Drug Dev Res 1996;39:393-406
   Web of Science ®Google Scholar
• Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature 2006;442:527-32
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Burnstock G, Boeynaems J-M, International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006;58(3):281-341
   PubMedGoogle Scholar
• Surprenant A, Rassendren F, Kawashima E, The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996;272(5262):735-8
   PubMed Web of Science ®Google Scholar
• Mager PP, Illes P, Walther H. Prediction of the conformation of the human P2X7 receptor. Lett Drug Des Discov 2006;3(10):675-82
   Google Scholar
• Mager PP. Subset selection and docking of human P2X7 inhibitors. Curr Comput Aided Drug Des 2007;3(4):248-53
   Google Scholar
• Teixeira PCN, de Souza CAM, de Freitas MS, Predictions suggesting a participation of beta-sheet configuration in the M2 domain of the P2X7 receptor: a novel conformation? Biophys J 2009;96(3):951-63
   PubMedGoogle Scholar
• Kawate T, Michel JC, Birdsong WT, Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 2009;460(7255):592-8
   PubMedGoogle Scholar
• Gonzales EB, Kawate T, Gouaux E. Pore architecture and ion sites in acid-sensing ion channels and P2X receptors. Nature 2009;460(7255):599-604
   PubMedGoogle Scholar
• Gunosewoyo H, Coster MJ, Kassiou M. Molecular probes for P2X7 receptor studies. Curr Med Chem 2007;14(14):1505-23
   PubMedGoogle Scholar
• Gunosewoyo H, Coster MJ, Bennett MR, Purinergic P2X7 receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg Med Chem 2009;17(14):4861-5
   PubMedGoogle Scholar
• Jarvis MF, Khakh BS. ATP-gated P2X cation-channels. Neuropharmacology 2009;56:208-15
   PubMedGoogle Scholar
• North RA. Molecular physiology of P2X receptors. Physiol Rev 2002;82(4):1013-67
   PubMed Web of Science ®Google Scholar
• Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol 2009;71:333-59
   PubMed Web of Science ®Google Scholar
• Inscho EW, Cook AK, Imig JD, Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. J Clin Invest 2003;112(12):1895-905
   PubMedGoogle Scholar
• Erhardt JA, Toomey JR, Douglas SA, P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation. J Thromb Haemost 2006;4:882-90
   PubMed Web of Science ®Google Scholar
• Mulryan K, Gitterman DP, Lewis C, Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 2000;403:86-9
   PubMed Web of Science ®Google Scholar
• Aventis Pharma Deutschland GmbH. Method for diagnosis of a predisposition to develop thrombotic disease based on the detection of a P2X1 promoter variant. WO2005095642; 2005
   Google Scholar
• King BF, Liu M, Pintor J, Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors. Br J Pharmacol 1999;128:981-8
   PubMed Web of Science ®Google Scholar
• Rettinger J, Braun K, Hochmann H, Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology 2005;48:461-8
   PubMed Web of Science ®Google Scholar
• Kassack MU, Braun K, Ganso M, Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem 2004;39:345-57
   PubMed Web of Science ®Google Scholar
• Mewburn Ellis LLP. 5-Methyl-6,7-dihydro-5H-cyclopentapyrazine for use in therapy, especially treating platelet-related diseases such as thrombosis, and as a male contraceptive. GB2439923; 2008
   Google Scholar
• Cockayne DA, Hamilton SG, Zhu Q-M, Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X 3-deficient mice. Nature 2000;407(6807):1011-5
   PubMedGoogle Scholar
• Cockayne DA, Dunn PM, Zhong Y, P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol 2005;567(2):621-39
   PubMedGoogle Scholar
• Finger TE, Danilova V, Barrows J, ATP signaling is crucial for communication from taste buds to gustatory nerves. Science 2005;310(5753):1495-9
   PubMedGoogle Scholar
• Jarvis MF, Wismer CT, Schweitzer E, Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X3 allosteric modulator, cibacron blue. Br J Pharmacol 2001;132:259-69
   PubMedGoogle Scholar
• Abbott Laboratories. Preparation of trisubstituted N-[(1S)-1,2,3, 4-tetrahydro-1-naphthalenyl] benzamides as inhibitors of P2X3 and P2X2/P2X3 containing receptors for treating pain, urinary incontinence and bladder overactivity. WO2002094767; 2002
   Google Scholar
• Jarvis MF, Burgard EC, McGaraughty S, A-317491, a novel potent and selective nonnucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. PNAS 2004;99(26):17179-84
   Google Scholar
• F. Hoffmann-La Roche AG. Diaminopyridines as P2X3 and P2X2/3 antagonists. WO2005095359; 2005
   Google Scholar
• Roche Palo Alto LLC. Diaminopyridines as P2X3 and P2X2/3 modulators. WO2007025899; 2007
   Google Scholar
• Roche Palo Alto LLC. Diaminopyridines as P2X3 and P2X2/3 modulators. WO2007025900; 2007
   Google Scholar
• Roche Palo Alto LLC. Diaminopyridines as P2X3 and P2X2/3 modulators. WO2007025901; 2007
   Google Scholar
• Roche Palo Alto LLC. Diaminopyridines as P2X3 and P2X2/3 modulators. WO2007025925; 2007
   Google Scholar
• Roche Palo Alto LLC. 2,4-Diaminopyridine derivatives and their use as P2X antagonists or as prodrugs thereof. WO2008104472; 2008
   Google Scholar
• Roche Palo Alto LLC. Diaminopyridines. WO2008104474; 2008
   Google Scholar
• Carter DS, Alam M, Cai H, Identification and SAR of novel diaminopyrimidines. Part 1: the discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain. Bioorg Med Chem Lett 2009;19(6):1628-31
   PubMedGoogle Scholar
• Jahangir A, Alam M, Carter DS, Identification and SAR of novel diaminopyrimidines. Part 2: the discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain. Bioorg Med Chem Lett 2009;19(6):1632-5
   PubMedGoogle Scholar
• Roche Palo Alto LLC. Piperidine and piperazine derivatives as P2X3 antagonists. WO2007020194; 2007
   Google Scholar
• F. Hoffmann-La Roche AG. Tetrazole-substituted arylamides as P2X2 and P2X2/3 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008000645; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of thiazole and oxazole-substituted arylamides as P2X3 and/or a P2X2/3 receptor antagonist. WO2008055840; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. Novel imidazole-substituted arylamides. WO2009077365; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Triazole-substituted arylamide derivatives and their use as p2x3 and /or p2x2/3 purinergic receptor antagonists. WO2009077366; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Novel pyrazole-substituted arylamides. WO2009077367; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists. WO2009077371; 2009
   Google Scholar
• Renovis, Inc. Preparation of fused heterocyclic compounds for preventing and treating various diseases. WO2006119504; 2006
   Google Scholar
• Renovis, Inc. Analgesic pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof. WO2008123963; 2008
   Google Scholar
• Renovis, Inc. Preparation of tetrahydropyrido[4,3-d]pyrimidine derivatives as modulators of P2X3 and P2X2/3 receptors. WO2008130481; 2008
   Google Scholar
• Astrazeneca AB. Preparation of 5,6-dihydro-7H-pyrrolo[3,4-d] pyrimidin-7-one derivatives as P2X3 receptor antagonists for treating especially pain. WO2008136756; 2008
   Google Scholar
• Merck & Co., IncBiarylcarboxamides as P2X3 receptor antagonists for treatment of pain and their preparation. WO2009058298; 2009
   Google Scholar
• Merck & Co., IncBiarylcarboxmides as P2X3 receptor antagonists for treatment of pain and their preparation. WO2009058299; 2009
   Google Scholar
• Shionogi & Co., LtdPreparation of pyrrolinone derivatives as P2X3 and/or P2X2/3 antagonists. WO2008120725; 2008
   Google Scholar
• Anygen Co., LtdPreparation of spinorphin derivatives as potent and selective human P2X3 receptor antagonist. WO2008114976; 2008
   Google Scholar
• Astellas Pharma, Inc. P2X receptor inhibitor. WO2005072746; 2005
   Google Scholar
• Gao Y, Xu C, Yu K, Effect of tetramethylpyrazine on DRG neuron P2X3 receptor involved in transmitting pain after burn. Burns 2009; doi:10.1016/j.burns.2009.04.032
   Google Scholar
• Bo X, Zhang Y, Nassar M, A P2X purinoceptor cDNA conferring a novel pharmacological profile. FEBS Lett 1995;375(1,2):129-33
   PubMedGoogle Scholar
• Buell G, Lewis C, Collo G, An antagonist-insensitive P2X receptor expressed in epithelia and brain. EMBO J 1996;15(1):55-62
   PubMedGoogle Scholar
• Japan Health Sciences Foundation. Drug screening of P2X4 receptor antagonists for treatment of neuropathic pain. US2005074819; 2005
   Google Scholar
• Yamamoto K, Sokabe T, Matsumoto T, Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med 2006;12(1):133-7
   PubMedGoogle Scholar
• Tsuda M, Shigemoto-Mogami Y, Koizumi S, P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003;424:778-83
   PubMed Web of Science ®Google Scholar
• Horvath RJ, DeLeo JA. Morphine enhances microglial migration through Modulation of P2X4 receptor signaling. J Neurosci 2009;29(4):998-1005
   PubMedGoogle Scholar
• Bayer Healthcare A-G. Benzofuro-1,4-diazepin-2-one derivative. WO2004085440; 2004
   Google Scholar
• Nippon Chemiphar Co., Ltd. Preparation of benzothieno [3,2-e]-1,4-diazepin-2-one derivatives or analogs thereof as P2X4 receptor antagonists. WO2007072974; 2007
   Google Scholar
• Nippon Chemiphar Co., Ltd. Preparation of benzofuro[3,2-e]-1, 4-diazepin-2-one derivatives as P2X4 receptor antagonists. WO2007074940; 2007
   Google Scholar
• Nippon Chemiphar Co., Ltd. Preparation of naphthodiazepinone derivatives as P2X4 receptor antagonists. WO2008023847; 2008
   Google Scholar
• Nippon Chemiphar Co., Ltd. Preparation of piperazine derivatives as P2X4 receptor antagonist. WO2009022730; 2009
   Google Scholar
• Kyushu University, National University Corp. P2x4 receptor antagonist. WO2007049825; 2007
   Google Scholar
• Kyushu University, National University Corp. P2x4 receptor antagonist. WO2008020651; 2008
   Google Scholar
• Guile SD, Alcaraz L, Birkinshaw TN, Antagonists of the P2X7 Receptor. From lead identification to drug development. J Med Chem 2009;52(10):3123-41
   PubMedGoogle Scholar
• Carroll WA, Donnelly-Roberts DL, Jarvis MF. Selective P2X7 receptor antagonists for chronic inflammation and pain. Purinergic Signal 2009;2009(5):63-73
   Google Scholar
• Romagnoli R, Baraldi PG, Cruz-Lopez O, The P2X7 receptor as a therapeutic target. Expert Opin Ther Targets 2008;12(5):647-61
   PubMedGoogle Scholar
• Astrazeneca AB; Astrazeneca UK Ltd. Preparation of quinolinecarboxyamide derivatives for use in the treatment of inflammatory diseases. WO2008114002; 2008
   Google Scholar
• Astrazeneca AB. Quinoline derivatives as a P2X7-receptor antagonist useful in the treatment of various diseases and its preparation. WO2009070116; 2009
   Google Scholar
• Astrazeneca AB; Astrazeneca UK Ltd. P2X7 antagonist use for treatment of mood disorder. WO2009019503; 2009
   Google Scholar
• ClinicalTrials.gov Available from: http://www.clinicaltrials.gov. [Accessed 10 December 2009]
   Google Scholar
• Renovis, Inc. Preparation of isoquinolonecarboxamides as P2X7 purinoceptor modulators and uses thereof. WO2008112205; 2008
   Google Scholar
• Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof. US2009170838; 2009
   Google Scholar
• Evotec. Available from: http://www.evotec.com/display/articleCategorized Detail/cms_article_id/67/ website_part_id/4. [Accessed 10 December 2009]
   Google Scholar
• Neurogen Corp. Preparation of heteroaryl amide analogs as P2X7 antagonists for treating pain and other disorders. WO2008124153; 2008
   Google Scholar
• Neurogen Corp. Preparation of 5-membered heterocyclic amides and related compounds as specific receptor activity modulators. WO2009012482; 2009
   Google Scholar
• Neurogen Corp. Preparation of heteroaryl amide analogs as P2X7 receptor modulators. WO2009023623; 2009
   Google Scholar
• Glaxo Group Ltd. Preparation of pyrrole and isoindole carboxamide derivatives as modulators of P2x7 receptor. WO2008116814; 2008
   Google Scholar
• Glaxo Group Ltd. Preparation of piperidinone carboxamide derivatives as P2x7 modulators. WO2008116845; 2008
   Google Scholar
• Glaxo Group Ltd. Preparation of morpholinecarboxamide derivatives and analogs as P2X7 modulators. WO2008119685; 2008
   Google Scholar
• Glaxo Group Ltd. Preparation of imidazolidinecarboxamide derivatives for use as P2X7 modulators. WO2008119825; 2008
   Google Scholar
• Glaxo Group Ltd. Pyrazole derivatives as P2X7 modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008125600; 2008
   Google Scholar
• Glaxo Group Ltd. Preparation of pyrazole derivatives as modulators of P2X7 receptor. WO2008138876; 2008
   Google Scholar
• Glaxo Group Ltd. Preparation of 4-benzoyl-1-substituted-piperazin-2-one derivatives as modulators of P2x7 receptors. WO2009053459; 2009
   Google Scholar
• Glaxo Group Ltd. Isothiazolidine 1,1-dioxide and tetrahydro-2h-1, 2-thiazine 1,1-dioxide derivatives as p2x7 modulators. WO2009077362; 2009
   Google Scholar
• Glaxo Group Ltd. Preparation of 5-oxo-3-pyrrolidinecarboxamide derivatives as P2x7 modulators for the treatment of pain, inflammation and neurodegenerative diseases. WO2009077559; 2009
   Google Scholar
• Neurogen Corp. Heteroaryl amide analogues. WO2009108551; 2009
   Google Scholar
• Schering Corp.; Albany Molecular Research, IncPolycyclic guanine derivatives and methods of use thereof. WO2009002423; 2009
   Google Scholar
• Nissan Chemical Industries, Ltd. Pyridazinone derivatives as P2X7 receptor inhibitors and their preparation, pharmaceutical compositions and use in the treatment of rheumatoid arthritis. WO2009057827; 2009
   Google Scholar
• Janssen Pharmaceutica. Quinoline or isoquinoline substituted P2X7 antagonists. WO2009132000; 2009
   Google Scholar
• Soliance, Fr. Modulation of the P2X7 receptor by hyaluronic acid derivatives. FR2918568; 2009
   Google Scholar
• Medicure International, Inc. Inhibition of ATP-mediated, P2X7-dependent pathways by pyridoxal-5-phosphate and vitamin B6 related compounds. US2009215727; 2009
   Google Scholar
• Neuroprotection of retinal ganglion cells. US2009220516; 2009
   Google Scholar
• GE Healthcare Ltd. Imaging the central nervous system. WO2009106564; 2009
   Google Scholar
• Lee J-Y, Yu J, Cho WJ, Synthesis and structure–activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists. Bioorg Med Chem Lett 2009;19:6053-8
   PubMedGoogle Scholar
• Affectis Pharmaceuticals. Novel P2X7R antagonists and their use. WO2009118175; 2009
   Google Scholar
• Yunaev MA, Barden JA, Bennett MR. Changes in the distribution of different subtypes of P2X receptor clusters on smooth muscle cells in relation to nerve varicosities in the pregnant rat urinary bladder. J Neurocytol 2000;29:99-108
   PubMedGoogle Scholar
• Katugampola H, Burnstock G. Purinergic signalling to rat ovarian smooth muscle: changes in P2X receptor expression during pregnancy. Cells Tissues Organs 2004;178(1):33-47
   PubMedGoogle Scholar
• Michel AD, Chambers LJ, Clay WC, Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br J Pharmacol 2007;151(1):103-14
   PubMedGoogle Scholar
• Michel AD, Chambers LJ, Walter DS. Negative and positive allosteric modulators of the P2X7 receptor. Br J Pharmacol 2008;153(4):737-50
   PubMedGoogle Scholar